Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Robert Huddart

Showing results (1-10 of 111) with videos related to

Pageof 12
Sort By:
Expert Review of Anticancer Therapy|September 30, 2014
Selective organ preservation for the treatment of muscle-invasive transitional cell carcinoma of the bladder: a review of current and future perspectivesShaista Hafeez, Robert Huddart
BMC Medicine|April 12, 2013
Advances in bladder cancer imagingShaista Hafeez, Robert Huddart
Lancet (London, England)|March 7, 2006
Testicular germ-cell cancerAlan Horwich, Janet Shipley, Robert Huddart
BMC Medicine|July 1, 2015
Exploration of the treatment challenges in men with intellectual difficulties and testicular cancer as seen in Down syndrome: single centre experienceShaista Hafeez, Mausam Singhera, Robert Huddart
Faculty Reviews|September 24, 2021
Recent advances in testicular germ cell tumoursTeresa Mele, Alison Reid, Robert Huddart
Nuclear Medicine Communications|October 30, 2025
A standardised attenuated dosing of 177 lutetium-prostate-specific membrane antigen therapy for patients with metastatic castration-resistant prostate carcinoma and preexisting renal impairmentDongni Du, Vincent Khoo, Robert Huddart, et al.
Expert Review of Anticancer Therapy|February 10, 2012
Minimizing toxicity in early-stage testicular cancer treatmentMausam Singhera, Kathryn Lees, Robert Huddart, et al.
European Urology|June 24, 2009
Surveillance in stage I seminoma patients: a long-term assessmentSebastian Cummins, Thomas Yau, Robert Huddart, et al.
Journal of Cancer|July 14, 2011
Is high dose therapy superior to conventional dose therapy as initial treatment for relapsed germ cell tumors? The TIGER TrialDarren R Feldman, Robert Huddart, Emma Hall, et al.
Trials|November 30, 2012
The Patient Deficit Model Overturned: a qualitative study of patients' perceptions of invitation to participate in a randomized controlled trial comparing selective bladder preservation against surgery in muscle invasive bladder cancer (SPARE, CRUK/07/011)Clare Moynihan, Rebecca Lewis, Emma Hall, et al.
Pageof 12

Showing results (1-10 of 111) with videos related to

Sort By:
Pageof 12
Expert Review of Anticancer Therapy|September 30, 2014
Selective organ preservation for the treatment of muscle-invasive transitional cell carcinoma of the bladder: a review of current and future perspectivesShaista Hafeez, Robert Huddart
BMC Medicine|April 12, 2013
Advances in bladder cancer imagingShaista Hafeez, Robert Huddart
Lancet (London, England)|March 7, 2006
Testicular germ-cell cancerAlan Horwich, Janet Shipley, Robert Huddart
BMC Medicine|July 1, 2015
Exploration of the treatment challenges in men with intellectual difficulties and testicular cancer as seen in Down syndrome: single centre experienceShaista Hafeez, Mausam Singhera, Robert Huddart
Faculty Reviews|September 24, 2021
Recent advances in testicular germ cell tumoursTeresa Mele, Alison Reid, Robert Huddart
Nuclear Medicine Communications|October 30, 2025
A standardised attenuated dosing of 177 lutetium-prostate-specific membrane antigen therapy for patients with metastatic castration-resistant prostate carcinoma and preexisting renal impairmentDongni Du, Vincent Khoo, Robert Huddart, et al.
Expert Review of Anticancer Therapy|February 10, 2012
Minimizing toxicity in early-stage testicular cancer treatmentMausam Singhera, Kathryn Lees, Robert Huddart, et al.
European Urology|June 24, 2009
Surveillance in stage I seminoma patients: a long-term assessmentSebastian Cummins, Thomas Yau, Robert Huddart, et al.
Journal of Cancer|July 14, 2011
Is high dose therapy superior to conventional dose therapy as initial treatment for relapsed germ cell tumors? The TIGER TrialDarren R Feldman, Robert Huddart, Emma Hall, et al.
Trials|November 30, 2012
The Patient Deficit Model Overturned: a qualitative study of patients' perceptions of invitation to participate in a randomized controlled trial comparing selective bladder preservation against surgery in muscle invasive bladder cancer (SPARE, CRUK/07/011)Clare Moynihan, Rebecca Lewis, Emma Hall, et al.
Pageof 12